CD8+抗BCMA mRNA CAR T细胞治疗多发性骨髓瘤的临床前评估
为拓宽CAR T细胞在社区诊所及一线治疗中的应用,研究者开发了新型CD8+ CAR T细胞产品Descartes-08,通过mRNA转染表达抗BCMA CAR。Descartes-08表达CAR约1周,可产生炎症细胞因子并高效裂解骨髓瘤细胞,且不受骨髓基质细胞、外源性APRIL或IMiDs耐药影响;在小鼠模型中显著抑制骨髓瘤生长并延长生存(p < 0.0001)。
要点
- Descartes-08为mRNA转染的CD8+ CAR T细胞,表达抗BCMA CAR约1周,限制失控增殖风险。
- 对骨髓瘤细胞高效裂解,不受骨髓基质细胞、外源性APRIL或IMiDs耐药影响。
- 小鼠模型中诱导BCMA CAR特异性骨髓瘤生长抑制并显著延长生存(p < 0.0001)。
核心结论
- Descartes-08在临床前研究中显示BCMA CAR特异性抗骨髓瘤活性并显著延长小鼠生存(p < 0.0001)。
- 上述临床前数据结合正在进行的复发/难治骨髓瘤临床试验(NCT03448978)初步持久缓解和良好治疗指数,为优化/人源化版本Descartes-11在新诊断诱导后残留病灶患者中启动试验提供了框架。
研究设计与样本
- 临床前研究:开发CD8+ CAR T细胞产品Descartes-08,通过mRNA转染表达抗BCMA CAR。
- 体外评估细胞因子产生和细胞毒作用;小鼠模型评估对侵袭性播散性人骨髓瘤的疗效。
主要发现
- Descartes-08表达抗BCMA CAR约1周,限制失控增殖风险。
- Descartes-08对骨髓瘤靶细胞产生炎症细胞因子,并对骨髓瘤细胞高度裂解,不受骨髓保护性基质细胞、外源性APRIL或包括IMiDs在内的耐药影响。
- 裂解程度与抗BCMA CAR表达持续时间相关,提示活性存在时间限制。
- 在小鼠侵袭性播散性人骨髓瘤模型中,Descartes-08诱导BCMA CAR特异性骨髓瘤生长抑制并显著延长宿主生存(p < 0.0001)。
临床怎么用
- 作者基于临床前数据及NCT03448978初步结果,为优化/人源化Descartes-11在新诊断诱导后残留病灶患者中的试验提供了框架。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for treatment of multiple myeloma. Descartes-08 is engineered by mRNA transfection to express anti-BCMA CAR for a defined length of time. Descartes-08 expresses anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of the presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs. The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity. In the mouse model of aggressive disseminated human myeloma, Descartes-08 induces BCMA CAR-specific myeloma growth inhibition and significantly prolongs host survival (p < 0.0001). These preclinical data, coupled with an ongoing clinical trial of Descartes-08 in relapsed/refractory myeloma (NCT03448978) showing preliminary durable responses and a favorable therapeutic index, have provided the framework for a recently initiated trial of an optimized/humanized version of Descartes-08 (i.e., Descartes-11) in newly diagnosed myeloma patients with residual disease after induction therapy.
引用
- Lin L, Cho SF, Xing L, et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2020. PMID: 32632095. doi:10.1038/s41375-020-0951-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。